 "Rusan Pharma invests Rs 100 crore in R&D, mfg unit at Kandla")
Rusan Pharma, which specialises in de-addiction and pain management products, is investing Rs 100 crore in a research and development centre and a manufacturing unit in Kandla. A clinical research organisation too is being set up as a part of its expansion plan.
Rusan Pharma said with the fresh investment, it will focus on research and manufacture of de-addiction and pain management drugs for domestic market and export and aims to double turnover to Rs 600 crore by 2018.
The company plans to manufacture transdermal patches at Kandla. Rusan Pharma exports products to Europe, Russia, South Africa, South East Asia and plans to expand exports to the US and Canada.
Navin Saxena, chairperson and founder of Rusan Pharma also announced a $20 million deal with the Brazilian government for its programme on smoking cessation.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app